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Introduction
Hip fractures are clearly less prevalent in 
our Black population, but unlike African 
American women, the spine bone mass 
and fracture rate of black and white 
South African women appear to be com-
parable.  In Europe and America, about 
25-30% of hip fractures occur in men; in 
developing countries including South 
Africa, men account for 50% of all hip 
fractures.  Approximately 20% of all hip 
fracture patients die within 1 year of the 
event; even more disconcerting is the 
fact that 50% are incapable of leading 
an independent life, and usually require 
institutionalisation.  It is furthermore pre-
dicted that the prevalence of fractures 
will increase in future, yet no more than 
10-20% of all women who sustain an 
osteoporotic fracture currently receive 
appropriate treatment for osteoporosis.
Definition of osteoporosis:
Originally defined on a histologic or clin-
ico-radiologic basis, the diagnosis of os-
teoporosis has for the past decade, de-
pended nearly entirely on the accurate 
measurement of bone mass (as bone 
mineral density, BMD) employing dual 
energy x-ray absorptiometry (DEXA), 
and its densitometric classification into 
normal, low BMD (osteopenia), osteopo-
rosis (OP) and severe OP categories.
While the four diagnostic categories of 
this WHO classification (Table I) have 
provided a practical basis to identify 
those at risk of sustaining a fracture, we 
do need to take cognisance of the limi-
tations of raising a risk factor for fracture 
(albeit an important one like BMD), to 
the status of a diagnostic criterium: 
i.  A single BMD measurement lacks 
sensitivity and up to 50% of patients 
with a known osteoporotic fracture 
may have a BMD value that is not in 
the osteoporosis range i.e. a BMD – 
the so-called T-score – which is 2.5 
SD or more below the peak value in 
young adults. 
ii.  The WHO criteria are based on data 
obtained from white postmenopaus-
al women employing DEXA of the ax-
ial skeleton, and cannot be extrapo-
lated to other populations (young in-
dividuals, Blacks, males) or to other 
techniques that measure BMD (e.g. 
QCT, ultrasound).  Under these cir-
cumstances, a diagnosis of OP is 
best considered if the so-called Z-
score (BMD compared with age, 
gender and race-matched controls) 
is below -2.  
iii.  Causes of a low BMD other than os-
teoporosis (e.g. primary hyperpara-
thyroidism, osteomalacia) are not 
considered 
iv.  Extraskeletal risk factors (e.g. pro-
pensity to falls) are not addressed. 
v.  Qualitative bone changes are not as-
sessed (Table II). 
Osteoporosis is a common, costly and serious disease.  The life-time risk of an osteoporotic fracture in Caucasian women ap-
proximates 50%.  Epidemiologic fracture data in South Africa are limited, but the incidence of osteoporosis appears to be similar 
in white, Indian and mixed ancestry (Coloured) females.  
Arthur Landau Lecture - reprinted from Transactions 2007;51(1): 30-35 with permission
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BMD or BMC < 1SD 





BMD or BMC 1 - 2.5SD 
below the mean of young 
healthy women
Osteoporosis
BMD or BMC > 2.5SD 




BMD or BMC > 2.5SD 
below the mean of young 
healthy women and the 
presence of one or more 
fragility fractures
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Numerous recent studies have empha-
sized the importance of bone quality as 
a major BMD - independent risk factor 
for fracture.  Unfortunately bone quality 
cannot readily be measured and surro-
gate markers (e.g. biochemical markers 
of bone turnover) therefore need to be 
employed (vide infra).
Pathophysiology and risk factors:
Since bone mass accounts for ap-
proximately 70% of the variance in bone 
strength in vitro, and is the only variable 
that can be accurately determined, its 
measurement (as BMD) currently em-
bodies the practical basis for the diag-
nosis of osteoporosis.
Bone mass is essentially a function of: 
i.  Peak bone mass (PBMD) attained 
during early adulthood. 
ii.  Age related bone loss 
iii  Total duration of loss  
  PBMD is largely (+70%) determined 
by heredity and gender, although 
nutrition (especially total energy 
and calcium intake), physical ac-
tivity, pubertal development and 
general health may exert a consid-
erable influence.  Age-related bone 
loss appears to result mainly from 
menopausal hormone deficiency 
(resulting in increased bone resorp-
tion), and progressive age-related 
osteoblast incompetence (resulting 
in impaired bone formation).  Ad-
ditional factors are, however, clearly 
operative but poorly understood 
(e.g. all women age and become 
Table III:  Risk Factors & Causes of Osteo-
porosis
• Genetic and ethnic factors
• Environmental factors
   – Lifestyle
      Diet
      Exercise
      Alcohol
      Smoking
   – Medical
      Hormones   
      Bone Toxins
      Malignant disorders
      Others   
• Age-related factors
   – Hypogonadism
   – Ageing
oestrogen deficient, yet not all de-
velop osteoporosis).  If genetic (both 
a maternal and paternal history of 
OP is important) or lifestyle factors 
(poor nutrition, lack of exercise, 
smoking and alcohol abuse), dis-
eases (e.g. endocrine, malignant, 
gut disorders), and/or bone toxic 
drugs (notably glucocorticoids, but 
also anti-epileptic agents, anti-co-
agulants, HAART, immunosuppres-
sive drugs etc) are superimposed 
on age-related (involutional) bone 
loss, significant osteoporosis may 
ensue (Table 3).
A number of risk factors for osteoporosis 
have been identified.  The weighting 
and prioritization of such risk factors 
may differ from one area to another, but 
the following factors are usually clinically 
useful to identify women at risk of sus-
taining an osteoporotic fracture: 
•  A low BMD (fracture risk doubles for 
each SD decrease in T-score) 
•  Advanced age
• Prior fragility 
•  Fracture (increases fracture risk five-
fold)
• A family history
•  Low body weight (BMI <19kg/m2) 
•  Chronic glucocorticoid use 
 (>3 months. regardless of dose)
•  Smoking and alcohol abuse
•  High risk of falls (previous history of 
falls; general frailty and sarcopenia; 
impaired balance, gait and reduced 




In South Africa, with its heterogeneous 
populations and limited health resourc-
es, the prevention and treatment of 
osteoporosis is best managed employ-
ing a case finding approach, and not a 
global screening policy.  It is suggested 
that clinical risk factors – related to bone 
mass (BMD), bone strength and/or falls 
– provide indications for further diagnos-
tic assessment.
The National Osteoporosis Foundation 
of South Africa (NOFSA) has therefore 
recommended the following indications 
for BMD measurement:  
i.  Diseases (endocrine, gut, malignant, 
nutritional/eating disorders) or drugs 
known to affect bone adversely 
ii.  Radiological evidence of vertebral 
deformity or osteopenia 
iii.  History of non-traumatic fracture 
after age 40 yr 
iv.  To facilitate the decision whether to 
initiate/continue HRT 
v.  The presence of strong historic risk 
factors (e.g. family history of OP, low 
BMI, heavy alcohol intake, smoking)
Dual energy x-ray absorptiometry 
(DEXA) of the axial skeleton is the pre-
ferred technique to measure BMD/
diagnose OP and to assess rates of 
bone loss/gain.  The BMD of both spine 
and hip should be measured and, until 
local reference ranges are established, 
it is recommended that the NHANES 
III reference data be used.  Since av-
erage hip and spine BMD values of 
black South African women and men 
are substantially lower than their African 
American counterparts, it is suggested 
that Causasion reference data be used 
in all our ethnic groups in the interim.
Radiological assessment of fracture
Standard radiology is too insensitive to 
be clinically useful for the early detection 
of bone loss – 30-40% of skeletal mass 
needs to be lost before loss can be 
reliably detected on plain radiographs. 
The routine radiological assessment 
of the spine for detection of vertebral 
fractures is, however, essential.  More 
than a third of all spine fractures are as-
ymptomatic, the patient being unaware 
of their presence.  Yet, the presence 
of vertebral fracture(s) increases the 
risk of a subsequent fracture 4-5 fold. 
Moreover, vertebral fractures are also 
indicators of increased risk of fractures 
at other sites, including the hip.
Morphometric assessment of the spine 
to detect vertebral fracture employing 
standard radiology or DEXA-based im-
aging (LVA, IVA) should therefore com-
prise a routine part of the work-up of any 
patient with possible osteoporosis.
Biochemical markers of bone-turnover
A high bone-turnover doubles the risk of 
fracture, independent of BMD.  Modern 
biochemical markers of bone resorp-
tion include urinary and serum deoxy-
pyridinoline, as well as collagen Type 
I cross-linked N (NTX) and C (CTX) 
telopeptides, while biomarkers of bone 
formation include serum osteocalcin, 
bone specific alkaline phosphatase 
(BALP), and C- (PICP) and N- (PINP) 
propeptides of Type I collagen.
In population studies, biomarkers have 
been shown to be useful predictors of 
bone loss, fracture risk independent of 
BMD, and response to anti-resorptive 
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therapy.  Technical and biological varia-
tions of up to 30% in individual subjects, 
however, limit their routine clinical use. 
They may be useful in problem cases 
(especially in the elderly) to aid in the 
decision whether to initiate treatment 
or not, and may be particularly useful to 
monitor therapy.
Biochemical assessment
Biochemical evaluation to exclude 
causes of a low BMD other than osteo-
porosis (primary hyperparathyroidism, 
osteomalacia) and to identify underly-
ing causes of osteoporosis should be 
considered in all patients with proven 
disease.  The former usually includes 
a serum calcium, phosphate and ALP 
– a serum parathyroid hormone and 25 
(OH) vitamin D level may also be con-
sidered.  A full blood count, ESR, protein 
electrophoresis and sex hormone levels 
in premenopausal subjects are routinely 
employed to identify secondary osteo-
porosis.  Further laboratory tests are 
generally dictated by clinical findings.
Diagnostic criteria vs. interventional 
thresholds;
Although useful in epidemiologic studies 
and drug trials, the largely BMD-based 
criteria to diagnose OP lack sensitivity 
(>50% of subjects with an osteoporotic 
fracture do not have a BMD in the OP 
range i.e. a T score below -2.5).  Similar 
to other chronic degenerative diseases 
like hypertensive stroke or dyslipidae-
mic coronary artery disease, the inter-
vention threshold or need to treat cannot 
depend on a mass-based diagnosis only 
– advanced age, prior fragility fractures, 
strong clinical risk factors (e.g. chronic 
glucocorticoid use), continuing bone 
loss (as indicated by an increased bone 
turnover) are but a few non-BMD deter-
minants of bone strength and propensity 
to fracture, which should be considered, 
in conjunction with a BMD measure-
ment, in the rational management of this 
disease (See Figure I).
Non-pharmacological measures to 
prevent osteoporotic fractures
Non-pharmacological measures to im-
prove bone strength include a balanced 
diet rich in dairy, physical exercise 
(weight bearing to improve bone mass, 
muscle strengthening to prevent falls), 
limiting alcohol consumption (2 units/day 
in both men and women; modest social 
drinking may have a bone protective 
effect in postmenopausal females), 
the avoidance of smoking and bone 
toxic drugs, and the prevention of falls 
(including the selective use of hip-pro-
tectors).
Pharmacologic interventions
Drugs used to treat osteoporosis are 
conventionally classified as antiresorp-
tive and bone formation stimulating 
agents. (Table IV).  These names are, 
however, misleading since the process 
of bone resorption and formation are 
coupled – even in most subsets of 
osteoporosis.  So-called antiresorptive 
drugs therefore decrease bone resorp-
tion (within weeks), and subsequently 
also bone formation (within months). 
Likewise, bone formation stimulating 
drugs like teriparatide augment bone 
formation, which is followed by an in-
crease in resorption a few months later.
which is markedly less than in Gauteng. 
Ethnicity and religious custom (covering 
sun exposed surfaces) may further limit 
vitamin D delivery.  Vitamin D supple-
mentation is recommended for all elder-
ly institutionalised patients.  If significant 
deficiency is suspected, measurement 
of serum 25-hydroxyvitamin D is recom-
mended.  High dose vitamin D treatment 
(50 000 IU, 1-4 times/2weeks) should 
include periodic determinations of 24h 
urinary calcium excretion.
Active metabolites of vitamin D, calcitriol 
and alfacalcidiol, were shown in ear-
lier studies to reduce the fracture rate 
– therapeutic and toxic doses seem to 
overlap and their routine use in the treat-
ment of osteoporosis cannot be recom-
mended.
HRT & SERMS
Data from the Women’s Health Initiative 
(WHI) have convincingly shown that 
treatment of postmenopausal women 
with oestrogen prevents fractures of 
both the spine and hip.  Hormone 
therapy is, however, not side-effect 
free and should probably be reserved 
for younger women (<60yr), especially 
those with menopausal symptoms.
Selective oestrogen receptor modula-
tors (SERMS) have been shown in the 
MORE study to reduce the risk of spine, 
but not hip fracture.  These agents also 
reduce breast cancer by 70%.
Bisphosphonates
Bisphosphonates are stable analogues 
of pyrophosphate which safely and ef-
fectively reduce the risk of spine and 
hip fractures, and remain the corner-
stone of antiresorptive therapy.  They 
do, however, have limitations related to 
long-term compliance, gastro-intestinal 
intolerance, poor absorption from the 
gut, and oversuppression of bone turn-
over (including osteonecrosis).  Intermit-
tent intravenous administration might 
address problems with compliance and 
absorption, and is the focus of much 
current research.
Teriparatide
Daily subcutaneous injections of human 
parathyroid hormone (hPTH 1-34) for as 
little as 21 months, markedly increase 
bone mass, improve skeletal micro-ar-
chitecture and reduce the risk of new 
vertebral fractures by 65% and non-
vertebral fractures by 35-40%.  Given 
its very high cost, the National Osteopo-
rosis Foundation (NOFSA) has recom-
mended that this drug should only be 
used in patients with severe OP i.e. (i) a 
low BMD plus 2 or more prevalent frac-
CPD Article
Table IV:  Drug Therapy for Osteoporosis
A. Anti-Resorptive Agents
     – Calcium
     – Vitamin D/Metabolites
     – Sex Hormones/SERMS
     – Calcitonins
     – Bisphosphonates
B. Anabolic / Dual Action Agents
     – Fluoride
     – Anabolic Steroids
     – Low - Dose Intermittent PTH
     – Strontium Salts
Calcium & Vitamin D
Calcium (ensuring a daily intake of 
1-1.5g) and vitamin D (800 IU/d) are 
routinely recommended for the pre-
vention and treatment of osteoporosis. 
Their effect on BMD is, however, often 
modest.  The ability of vitamin D (with 
or without calcium) to reduce vertebral 
fracture seems to be well documented, 
but effects on the rate of hip fracture 
remain controversial and apparently 
dependent, at least in part, on the study 
population – frail elderly subjects with 
a low dietary calcium intake and a low 
serum 25-hydroxyvitamin D appear to 
respond better.  One of the major prob-
lems with calcium supplementation is 
poor compliance which can usually be 
ascribed to gastro-intestinal side-effects, 
particularly constipation.
It is important to note that sun exposure 
during winter in the Western Cape, re-
sults in the activation of previtamin D 









































Fig 1: Algorithm to assess whether to intervene in patients with possible osteoporosis. The intervention threshold or need to intervene should  
  not depend on a mass-based diagnosis only, but should also take into consideration various patient, disease and treatment factors. 
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tures or (ii) failed antiresorptive therapy 
i.e. after adhering to adequate antire-
sorptive therapy for 12 months or more, 
the patient experiences: (a) an incident 
fracture or (b) an unacceptable rate of 
bone loss (e.g. a decrease in vertebral 
BMD of >5% per year as documented 
on 2 or more follow-up BMD measure-
ments).  Currently consideration is being 
given to extend these indications – e.g. 
to include glucocorticoid-induced os-
teoporosis.
Strontium ranelate
Strontium ranelate has a unique dual ac-
tion on the skeleton – it stimulates bone 
formation whilst it also decreases bone 
resorption.  This results in a marked in-
crease in bone mass, size and strength, 
as well as a significant reduction in 
the risk of vertebral (SOTI-trial) and 
non-vertebral (TROPOS-trial) fractures 
of 41-52% and 36% respectively.  In 
these trials, compliance with the drug 
was good and side-effects did not differ 
significantly from that of controls.
Other drugs
Calcitonin has a direct-inhibitory effect 
on osteoclast action and also has cen-
tral opiate-mediated analgesic proper-
ties.  Its anti-fracture efficacy is, however, 
poorly documented.
Fluoride is a potent osteoblast mitogen, 
which stimulates bone formation and 
significantly increases BMD. It also 
causes a dose-dependent mineralisa-




Recent advances in osteoclast biology, 
in particular our understanding of the 
RANKL/OPG system, lysosomal cyste-
ine proteinases and intracellular acidifi-
cation, have led to the development of a 
number of new and exciting antiresorp-
tive agents – these include OPG ana-
logues, RANKL inhibitors, disintegrins 
which bind and inhibit osteoclast αVβ3, 
carbonic anhydrase II (CA2) modula-
tors, Cathepsin K inhibitors and more.
New bone formation stimulators
Mitogens and growth factors are difficult 
to target exclusively to bone and there-
fore have limited therapeutic potential at 
present.  Sclerostin is however a novel 
bone morphogenetic protein (BMP)-
antagonist, expressed exclusively in 
bone.  Mutations in the SOST-gene 
which codes for sclerostin, results in the 
sclerotic bone disease called scleroste-
osis – inhibitors of sclerostin have been 
developed and are now being tested as 
novel anabolic agents.
A rational choice of drug therapy
Given the clinical, histological and bio-
chemical heterogeneity of osteoporosis, 
no “best drug scenario” to optimally 
treat this condition is appropriate.  In 
fact, fracture reduction has not been 
assessed in head-to-head trials, so it is 
not possible to compare the efficacy of 
bone active agents directly.  The choice 
of drug(s) to manage osteoporosis 
should therefore be determined by: 
i.  The nature of the disease (e.g. 
calcium/vitamin D for mild osteope-
nia; bisphosphonates for osteoporo-
sis; and the addition of an anabolic 
agent in patients with severe osteo-
porosis
ii.  The patient profile (e.g. bisphos-
phonates or strontium ranelate in 
otherwise healthy subjects requiring 
a bone specific agent; HRT in young 
postmenopausal women with trou-
blesome menopausal symptoms, 
SERMS for those at risk of breast 
cancer etc.),
iii.  Cost-effectiveness, side-effects and 
availability of drugs ( Table V )
years after initiating treatment with these 
drugs.  The magnitude of the increase 
depends in part on initial bone turnover 
– absence of an increase in BMD should 
not be seen as a therapeutic failure.
Morphometry.  Vertebral imaging (x-
rays, LVA IVA) every + 3 years is essen-
tial to assess the efficacy of treatment.
Biochemistry.  Biomarkers of bone turn-
over hold much promise, but large bio-
logical and technical variations limit their 
routine use in individual patients.
Conclusion
Recent advances in the field of osteo-
porosis have involved both fundamental 
conceptual changes in our understand-
ing of its definition and natural evolution 
on the one hand, as well as a number 
of technological developments on the 
other.  The former have highlighted the 
limitations of a largely BMD-based diag-
nosis; emphasized the importance of 
bone quality and BMD-independent risk 
factors of osteoporosis; and stressed 
the need to distinguish between simple 
diagnostic criteria and often complex 
interventional thresholds.  The latter 
have largely confirmed the efficacy and 
safety of antiresorptive drugs like the 
bisphosphonates in large randomised 
controlled trials (RCTs); cautioned 
against the use of agents which had not 
previously been subjected to rigorous 
RCTs (e.g. use of HRT prior to the WHI); 
and included the launch of new anabolic 
(teriparatide) and dual-action (strontium 
ranelate) drugs.  Improved understan-
ding of bone biology has further led to 
the development of a vast array of bone 
active drugs which will enable the care 
physician to efficiently and safely treat 
even advanced cases of osteoporosis 
in a rational and scientific way.  
See CPD Questionnaire, page 42
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